Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Entera Bio Ltd. (NASDAQ: ENTX) will participate virtually in the H.C.

Rhea-AI Summary

Entera Bio Ltd. (NASDAQ: ENTX) will participate virtually in the H.C. Wainwright Global Investment Conference on September 15, 2020, at 3:00 p.m. EDT. Investors can access a live webcast of the presentation via the company’s website, with a replay available for 45 days after. Entera specializes in the development of orally delivered large molecule therapeutics for conditions like osteoporosis and hypoparathyroidism, leveraging proprietary technology to improve absorption and delivery. The company's candidates EB613 and EB612 are currently in Phase 2 clinical trials.

Argus Session date unavailable

+6.60% session move Open Argus

Details

News Market Reaction – ENTX

The recorded move for ENTX in the trading session of this news was +6.60%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2020 at 3:00 p.m. EDT.

To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click here. A replay of the webcast will be archived on Entera’s website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Entera Bio participate in the H.C. Wainwright Global Investment Conference?

Entera Bio will participate virtually in the conference on September 15, 2020, at 3:00 p.m. EDT.

How can I access the Entera Bio webcast?

Investors can access the live webcast on Entera's 'Investor Relations' page, with a replay available for 45 days.

What is Entera Bio's focus in drug development?

Entera Bio focuses on the development of orally delivered large molecule therapeutics for conditions with significant unmet medical needs.

What are the advanced product candidates of Entera Bio?

Entera Bio's advanced product candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.

Who has Entera Bio partnered with for its technology?

Entera Bio has established a collaboration with Amgen for licensing its oral drug delivery technology.